Skip To Main Content
Emily Barrett on Muck Rack

Emily Barrett

As seen in: Environmental Health Perspectives, MSN, Nature, Frontiers, MDPI, JAMA (The Journal of the American Medical Association), JAMA Network, Healio, American Journal of Public Health, Fertility and Sterility and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Emily

Contact Emily, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Life’s Essential 8 in Pregnancy and Time to Incident Cardiometabolic Disease Over 7 Years Follow-Up

|
By Ellen Francis, Shalin Patel, Alexa Freedman, Lauren S Keenan-Devlin, Linda M. Ernst, Emily Barrett, Ann Borders, Gregory Miller, Shristi Rawal, Amy Crockett, Anushka Pande
| JAMA Network Verified
1. Lewey J, Beckie TM, Brown HL, et al. Opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes: a scientific statement from the American Heart Association.   Circulation. 2024;149(7):e330-e46. doi:10.1161/CIR.0000000000001212Google ScholarCrossref 2. Parikh NI, Gonzalez JM, Anderson CAM, et al.
Open in Who Shared Issue with article?

Diet and mycoestrogen exposure in a pregnancy cohort: the Jersey Babies pilot study

|
By Zorimar Rivera-Núñez, Carolyn W. Kinkade, Megan Hansel, Jessica Fields, Todd Rosen, Kristy Palomares, Brian Buckley, Lauren M. Aleksunes, Emily Barrett, Alyssa Juenke, Daniel Heltberg, Aditi Sharada, Shabree Anthony, Anita Brinker
| Nature Verified
Abstract Zearalenone (ZEN) is a grain-contaminating mycotoxin and potent estrogen receptor agonist linked to reproductive and perinatal disruption in animal models, with emerging epidemiologic evidence in humans. Despite widespread U.S. exposure, dietary sources remain unclear. This pilot study assessed prenatal mycoestrogen exposure and related dietary sources in a U.S. pregnant cohort.
Open in Who Shared Issue with article?

Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial

|
By Joyce O’Shaughnessy, François-Clément Bidard, Patrick Neven, Mónica Casalnuovo, Philippe Aftimos, Cristina Saura, Nadia Harbeck, Lisa Carey, Giuseppe Curigliano, Jose A Garcia-Saenz, Maria Fernandez Abad, Larissa de Paula, Yeon Hee Park, Ozgur Ozyilkan, Maria Munoz, Maria Muñoz, Emily Barrett, Shanshan Cao, Aarti Chawla, Komal Jhaveri
| Nature Verified
Abstract In EMBER-3 (NCT04975308), among patients with ER + , HER2- advanced breast cancer (ABC) with recurrence/progression on/after endocrine therapy (ET), imlunestrant significantly prolonged PFS versus standard ET in patients with ESR1 mutations, and imlunestrant + abemaciclib prolonged PFS versus imlunestrant in the overall population. We report the incidence, severity, timing, and management of common treatment-emergent adverse events (TEAEs), including safety profiles of select subgroups.
Open in Who Shared Issue with article?
See all 52 articles